Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Actuate Therapeutics Inc.
Eli Lilly and Company
Emory University
Pediatric Brain Tumor Consortium
Medical University of South Carolina
Reveal Pharmaceuticals Inc.
University Hospital, Lille
University of Kentucky
University of Zurich
National Institutes of Health Clinical Center (CC)
University of Milano Bicocca
Dana-Farber Cancer Institute
Pfizer
University of California, San Diego
University of Virginia
Seattle Children's Hospital
Novartis
Hoffmann-La Roche
TVAX Biomedical
Wake Forest University Health Sciences
University of Alabama at Birmingham
Jubilant DraxImage Inc.
DNAtrix, Inc.
Memorial Sloan Kettering Cancer Center
Huashan Hospital
Celldex Therapeutics
Novartis
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
The Cooper Health System
Masonic Cancer Center, University of Minnesota
University of Michigan Rogel Cancer Center
University of Kentucky
University of Utah
China Medical University Hospital
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
The Hospital for Sick Children
University of Utah
National Cancer Institute (NCI)
Barretos Cancer Hospital
Isarna Therapeutics GmbH
National Cancer Institute (NCI)
University Hospital Muenster
University Hospital, Bordeaux
European Organisation for Research and Treatment of Cancer - EORTC
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital